GlassScriptPhysician profile
Dianne M Cooper
NPI 1649232810
$249,620.85
in general payments reported to CMS, 2019-2025
36 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $28K · 2021: $29K · 2022: $26K · 2023: $45K · 2024: $29K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $28K · Food and Beverage: $12K · Honoraria: $5,250 · Consulting Fee: $2,763 · Education: $44.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,897.50 |
| Travel and Lodging | $28,223.75 |
| Food and Beverage | $12,180.92 |
| Honoraria | $5,250.00 |
| Consulting Fee | $2,762.50 |
| Education | $44.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $122,620.31 | 2019-2025 | Benlysta |
| Amgen INC. | $78,814.18 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Celgene Corporation | $15,758.86 | 2019 | |
| Horizon Therapeutics Plc | $8,515.11 | 2019-2023 | Krystexxa, Tepezza |
| Ucb, INC. | $4,987.69 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Scientific Affairs, LLC | $4,045.82 | 2019-2024 | Tremfya |
| Janssen Biotech, INC. | $2,911.16 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,757.02 | 2019-2025 | Rinvoq, Ubrelvy, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $1,442.63 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,270.61 | 2019-2025 | Orencia |
| Pfizer INC. | $1,199.28 | 2019-2025 | |
| Genentech USA, INC. | $900.47 | 2019-2025 | Actemra, Rituxan |
| Ani Pharmaceuticals, INC. | $851.57 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $745.95 | 2019-2024 | Taltz |
| Genzyme Corporation | $690.02 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $565.61 | 2019-2025 | |
| Radius Health, INC. | $394.65 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.76 | 2020-2025 | Ofev, Cyltezo, Jascayd |
| Lundbeck LLC | $109.20 | 2022-2023 | Vyepti |
| Novo Nordisk INC | $105.74 | 2024-2025 | Wegovy |
| Sobi, INC | $99.43 | 2021-2025 | |
| Depuy Synthes Sales INC. | $92.26 | 2021-2025 | Monovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $62.77 | 2019-2023 | Cuvitru |
| Zyla Life Sciences, INC. | $62.24 | 2019-2020 | |
| Shield Therapeutics INC | $56.36 | 2025 | |
| Tersera Therapeutics LLC | $55.58 | 2025 | Quzyttir |
| Si-Bone, INC. | $55.11 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $27.24 | 2024 | Idacio |
| Pacira Therapeutics, INC. | $26.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.60 | 2019 | |
| Sandoz INC. | $20.45 | 2024 | Hyrimoz |
| Almatica Pharma LLC | $19.96 | 2024 | Teriparatide |
| Aurinia Pharma U.S., INC. | $18.99 | 2023 | Lupkynis |
| Mdd US Operations, LLC | $15.42 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.11 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.